Maravai Lifesciences Holdings Stock Beta
| MRVI Stock | USD 3.07 0.16 4.95% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Maravai Lifesciences' long-term financial health and intrinsic value.
Maravai | Beta | Build AI portfolio with Maravai Stock |
Maravai Lifesciences Holdings Company Beta Analysis
Maravai Lifesciences' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Maravai Lifesciences Beta | 0.33 |
Most of Maravai Lifesciences' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Maravai Lifesciences Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Maravai Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Maravai Lifesciences is extremely important. It helps to project a fair market value of Maravai Stock properly, considering its historical fundamentals such as Beta. Since Maravai Lifesciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Maravai Lifesciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Maravai Lifesciences' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Maravai Lifesciences Holdings has a Beta of 0.331. This is 61.51% lower than that of the Life Sciences Tools & Services sector and 76.19% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Maravai Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Maravai Lifesciences' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Maravai Lifesciences could also be used in its relative valuation, which is a method of valuing Maravai Lifesciences by comparing valuation metrics of similar companies.Maravai Lifesciences is currently under evaluation in beta category among its peers.
Maravai Lifesciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Maravai Lifesciences from analyzing Maravai Lifesciences' financial statements. These drivers represent accounts that assess Maravai Lifesciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Maravai Lifesciences' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 5.2B | 9.2B | 3.6B | 1.6B | 1.4B | 1.4B | |
| Enterprise Value | 5.5B | 9.2B | 3.5B | 1.7B | 1.5B | 1.4B |
Maravai Lifesciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Maravai Lifesciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Maravai Lifesciences' managers, analysts, and investors.Environmental | Governance | Social |
Maravai Lifesciences Institutional Holders
Institutional Holdings refers to the ownership stake in Maravai Lifesciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Maravai Lifesciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Maravai Lifesciences' value.| Shares | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 2.9 M | T. Rowe Price Investment Management,inc. | 2025-06-30 | 2.6 M | Philosophy Capital Management Llc | 2025-06-30 | 2.6 M | State Street Corp | 2025-06-30 | 2.4 M | Two Sigma Advisers, Llc | 2025-06-30 | 2.2 M | Tejara Capital Ltd | 2025-06-30 | 1.9 M | Deutsche Bank Ag | 2025-06-30 | 1.9 M | Systematic Financial Management Lp | 2025-06-30 | 1.7 M | Centerbook Partners Lp | 2025-06-30 | 1.6 M | Gtcr Llc | 2025-06-30 | 20.2 M | 12 West Capital Management Lp | 2025-06-30 | 12.5 M |
As returns on the market increase, Maravai Lifesciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Maravai Lifesciences is expected to be smaller as well.
Maravai Fundamentals
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.0589 | ||||
| Profit Margin | (0.88) % | ||||
| Operating Margin | (0.75) % | ||||
| Current Valuation | 523.37 M | ||||
| Shares Outstanding | 144.68 M | ||||
| Shares Owned By Insiders | 10.16 % | ||||
| Shares Owned By Institutions | 89.85 % | ||||
| Number Of Shares Shorted | 13.43 M | ||||
| Price To Earning | 7.79 X | ||||
| Price To Book | 1.62 X | ||||
| Price To Sales | 5.38 X | ||||
| Revenue | 259.19 M | ||||
| Gross Profit | 67.12 M | ||||
| EBITDA | (156.92 M) | ||||
| Net Income | (259.62 M) | ||||
| Cash And Equivalents | 617.45 M | ||||
| Cash Per Share | 4.69 X | ||||
| Total Debt | 376.69 M | ||||
| Debt To Equity | 0.69 % | ||||
| Current Ratio | 7.22 X | ||||
| Book Value Per Share | 1.84 X | ||||
| Cash Flow From Operations | 7.46 M | ||||
| Short Ratio | 7.98 X | ||||
| Earnings Per Share | (1.37) X | ||||
| Price To Earnings To Growth | (0.22) X | ||||
| Target Price | 4.0 | ||||
| Number Of Employees | 560 | ||||
| Beta | 0.33 | ||||
| Market Capitalization | 1.18 B | ||||
| Total Asset | 1.01 B | ||||
| Retained Earnings | 140.89 M | ||||
| Working Capital | 372.18 M | ||||
| Net Asset | 1.01 B |
About Maravai Lifesciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Maravai Lifesciences Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Maravai Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Maravai Lifesciences Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| VOO | Vanguard SP 500 | |
| XLK | Technology Select Sector | |
| XLV | Health Care Select | |
| QQQ | Invesco QQQ Trust | |
| XLC | Communication Services Select |
Check out Maravai Lifesciences Piotroski F Score and Maravai Lifesciences Altman Z Score analysis. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Maravai Lifesciences. If investors know Maravai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Maravai Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.33) | Earnings Share (1.37) | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets |
The market value of Maravai Lifesciences is measured differently than its book value, which is the value of Maravai that is recorded on the company's balance sheet. Investors also form their own opinion of Maravai Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Maravai Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Maravai Lifesciences' market value can be influenced by many factors that don't directly affect Maravai Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Maravai Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Maravai Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Maravai Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.